Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

332.75 +0.14 (+0.04%)
Streaming Delayed Price Updated: 10:17 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 269,638
Open 328.86
Bid (Size) 332.43 (40)
Ask (Size) 333.08 (40)
Prev. Close 332.61
Today's Range 324.53 - 332.75
52wk Range 205.87 - 495.55
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Alnylam Pharmaceuticals Stock Was Soaring on Monday ↗
One pundit tracking the company upgraded his recommendation. 
Via The Motley Fool
News headline image
Why Alnylam Pharmaceuticals Stock Slipped Today ↗
The company's Amvuttra is proving to be quite the motor of growth these days. 
Via The Motley Fool

Performance

YTD
-16.8%
-16.8%
1 Month
-6.4%
-6.4%
3 Month
-28.0%
-28.0%
6 Month
-27.4%
-27.4%
1 Year
+33.1%
+33.1%

More News

Read More
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
Via Finterra
Topics Economy Intellectual Property
Alnylam Pharmaceuticals (NASDAQ:ALNY) Fits the 'Affordable Growth' GARP Profile ↗
Via Chartmill
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Candidate with Strong Growth and Fair Valuation ↗
Via Chartmill
News headline image
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Should You Buy Alnylam Pharmaceuticals Before Feb. 12? ↗
Via The Motley Fool
Topics Earnings
News headline image
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
Via PredictStreet
Topics Economy Intellectual Property Stocks
News headline image
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A Prime GARP Candidate for Affordable Growth ↗
Via Chartmill
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
Via The Motley Fool
News headline image
Alnylam Pharmaceuticals Announces Changes to Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗
Via Investor's Business Daily
News headline image
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗
Via Benzinga
News headline image
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗
Via Investor's Business Daily
Topics Death
News headline image
What Does the Market Think About Alnylam Pharmaceuticals Inc? ↗
Via Benzinga
News headline image
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 332.75
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 02/18/26 10:17 AM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 39.55B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 40B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.